Pneumococcal infections ... have had a severe allergic reaction to any PCV vaccine or any vaccine containing diphtheria ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

Three years after the start of the COVID-19 pandemic, coverage for selected routine childhood vaccines remained below prepandemic levels.

Applied in a vaccination program, the 7-valent pneumococcal conjugate vaccine (PCV7) in a 2+1 dose schedule appears to be highly effective. Conjugate vaccines with more than seven serotypes will ...

With respect to this article, I noted the company's enormous potential to advance its Pneumococcal Conjugate Vaccine [PCV] candidate VAX-24 to prevent invasive pneumococcal disease [IPD] in ...

Although the effect of heptavalent pneumococcal conjugate vaccine (PCV7) has been demonstrated in all pre-registration and postmarketing studies, its real effect on the incidence of AOM cannot be ...

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal ... of innovative work in PCV," remarked Sanofi's head of vaccines, Thomas Triomphe.

Get Instant Summarized Text (Gist) Coverage for routine childhood vaccines, including rotavirus, diphtheria, tetanus, acellular pertussis, and pneumococcal conjugate, remains below prepandemic ...

Other pipeline advancements include atirmociclib, a CDK4 inhibitor for breast cancer entering Phase 3 trials, as well as PCV-25, a next-generation pneumococcal vaccine entering Phase 3 trials in 2025.

which has enabled it to create a broad coverage pneumococcal vaccine (PCV) that is unlikely to be matched by large pharma competitors. By solving a known limitation of current vaccine chemistry ...